NeuroMab™ Anti-IL-6 Antibody(NRP-0422-P1510)

Figure 1 depicts mean plasma CRP concentrations following a single intravenous injection in patients with advanced cancer. Ab1 (ALD518) was infused at 80, 160 or 320 mg (n=8).

Figure 2 depicts mean serum CRP levels in rheumatoid arthritis patients with an inadequate response to methotrexate following administration of 80, 160, or 320 mg of Ab1(ALD518).

Figure 3 shows that Ab1 increased mean hemoglobin concentration (g/dL) by 80, 160 and 320 mg after 12 weeks of administration in NSCLC patients compared to placebo.

Figure 4 depicts Ab1 increasing mean albumin concentrations at 80, 160 and 320 mg in NSCLC patients.

Figure 5 graphically illustrates the mean change in SF-36 composite score at week 12 in a phase II clinical trial of ALD518 administered to patients with active RA.

Figure 6 depicts the relationship between WHO oral mucositis grade and cumulative IMRT (Gy): Three patients received ALD518 160 mg intravenously at weeks 0 and 4.